Recent studies have converged on the overlap of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|glucagon receptor agonist therapies and dopamine signaling. While GIP activators are increasingly employed for managing type 2 diabetes mellitus, their potential impacts on motivation circuits, specifically governed by dopaminergic n